Thinking, daily life and mood in dementia and mild cognitive impairment
Studies thinking, daily life and mood in dementia and MCI.
Key facts
- Who runs it
- IRCCS Centro Neurolesi Bonino Pulejo
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Dementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms.
- Status
- Recruiting
- People taking part
- 151 people, planned
- Started
- Dec 2025
- Expected to end
- 20 Dec 2026
- Type of study
- Observational
- Treatments tested
- none - observational study
- Record updated
- 17 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with suspected or confirmed dementia or mild cognitive impairment (MCI). They must be referred to the neuropsychology clinic for a first assessment or follow-up.
- Age
- 50 to 86 years
- Sex
- All sexes
- Disease stage
- Suspected or confirmed dementia or mild cognitive impairment (MCI). No behavioral, psychiatric or sensory problems severe enough to get in the way of memory and thinking tests or questionnaires.
- Earlier treatment
- People cannot join if they take medicines that strongly affect thinking (such as sedatives or high-dose antipsychotics) and the dose is not yet stable.
Main reasons for not taking part
- Other brain or nerve diseases, such as recent stroke, severe head injury, epilepsy or multiple sclerosis
- Unstable major mental illness, such as schizophrenia, active bipolar disorder or untreated severe depression
- Severe sight or hearing problems that are not corrected and affect the tests
- Medicines that strongly affect thinking and are not at a stable dose
- Terminal illness, cancer or other illness that strongly interferes with the assessments
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age between 50 and 86 years
- Suspected or confirmed diagnosis of dementia or mild cognitive impairment (MCI)
- Referral to the neuropsychology clinic for initial assessment or clinical monitoring
- Absence of behavioral, psychiatric, or sensory disorders severe enough to significantly impair cognitive testing or completion of questionnaires
Who cannot take part
- Use of medications with significant cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of evaluation
- Presence of neurological disorders other than dementia or MCI (e.g., recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, atypical neurodegenerative diseases)
- Unstable major psychiatric comorbidities at the time of assessment (e.g., schizophrenia, bipolar disorder in active phase, untreated severe depression)
- Presence of terminal medical or oncological conditions or other illnesses significantly interfering with the assessment procedures
- Uncorrected severe sensory deficits (visual or auditory) affecting the validity of cognitive or functional assessments
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 86 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Dementia, in its various forms, is characterized by a generalized cognitive decline that can significantly compromise personal autonomy and quality of life. Mild Cognitive Impairment (MCI), although not classified as an overt form of dementia, represents a condition at evolutionary risk and is considered a crucial transitional stage for the early detection of cognitive decline. Understanding the impact of dementia and MCI from a multidimensional perspective is now essential to fully grasp the repercussions of these conditions on patients' daily lives. The present protocol aims to investigate key aspects related to these disorders, with the objective of exploring cognitive functioning, the degree of impairment in activities of daily living, and the presence of neuropsychiatric symptoms. Through an integrated and multidisciplinary approach, the study seeks to enhance clinical management and patient care, promoting more effective, targeted, and personalized interventions.
Treatments tested
- none - observational study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Dementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms.
- Plain-language title
- Thinking, daily life and mood in dementia and mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT07287410, who can take part
- Publications
- Evaluation of functional autonomy and neuropsychiatric symptoms in dementia and Mild Cognitive Impairment: a retrospective observational protocol.Neurodegenerative disease management, 2026
- Record updated
- 17 December 2025